Exclusivity. The Parties’ respective obligations set forth in [Section 10.8] will survive and continue to apply to a Reversion Product until the earlier of # such time as no further payments are owed by the Continuing Party to the Opt-Out Party for such Reversion Product in such country, # such time as the Continuing Party provides written notice to the Opt-Out Party of its decision, in its sole discretion, to cease permanently the Research, Development and Commercialization of such Reversion Product (which notice will be provided within ​ of the Opt-Out Party making such decision), and # the Opt-Out Party has terminated the Continuing Party’s license with respect to such Reversion Product as provided in [Section 3.3(j)]. For clarity, [Section 10.9] and [Section 18.5(b)] through [Section 18.5(d)] will continue to apply to the Reversion Product.

Termination. On a Reversion Product-by-Reversion Product untilbasis, # the earlier ofOpt-Out Party will have the right to terminate this Agreement) in accordance with [[Sections 16.3(a)(i), 16.3(a)(ii) and 16.3(a)(iii)])])]])] (but, for clarity, not [Section 16.3(a)(iv)]) with respect to the applicable Reversion Product, and # such time as no further payments are owed by the Continuing Party will have the right to the Opt-Out Party for such Reversion Product in such country, # such time as the Continuing Party providesterminate this Agreement upon written notice to the Opt-Out Party of itsthe Continuing Party’s decision, in its sole discretion, to cease permanently the Research, Development and Commercialization of such Reversion Product (which notice will be provided within ​ of the Opt-OutContinuing Party making such decision), and #. In the Opt-Out Party has terminated the Continuing Party’s licenseevent of a termination of this Agreement with respect to sucha Reversion Product, then the consequences in [Section 16.5(b)] will apply. For clarity, any termination of this Agreement with respect to a Reversion Product as providedwill result in [Section 3.3(j)]. For clarity, [Section 10.9] and [Section 18.5(b)] through [Section 18.5(d)] will continue to apply to the Reversion Product.termination of the applicable Collaboration Antigen.